Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 10-Apr-24 8:50 PM View:  | Friedman Paul A Director | Synta Pharmaceuticals Corp. (MDGL) | 08-Apr-24 | Planned Option Sale | 26,270 | $246.19 | $6,467,490.00 | (3%) 867.54K to 841.27K | |
| 10-Apr-24 8:53 PM View: | Taub Rebecca Pres., R&D, and CMO Director | Synta Pharmaceuticals Corp. (MDGL) | 08-Apr-24 | Option Exercise | 2,676 | $9.45 | $25,288.20 | < 1% 1.11M to 1.12M | |
| 10-Apr-24 8:53 PM View: | Taub Rebecca Pres., R&D, and CMO Director | Synta Pharmaceuticals Corp. (MDGL) | 08-Apr-24 | Planned Option Sale | 2,676 | $245.99 | $658,258.00 | (< 1%) 1.12M to 1.11M | |
| 10-Apr-24 8:50 PM View: | Friedman Paul A Director | Synta Pharmaceuticals Corp. (MDGL) | 08-Apr-24 | Option Exercise | 26,270 | $9.45 | $248,252.00 | 3% 841.27K to 867.54K | |
| 05-Apr-24 8:50 PM View: | Taub Rebecca Pres., R&D, and CMO Director | Synta Pharmaceuticals Corp. (MDGL) | 05-Apr-24 | Planned Option Sale | 27,506 | $243.36 | $6,693,790.00 | (2%) 1.14M to 1.11M | |
| 05-Apr-24 8:50 PM View: | Friedman Paul A Director | Synta Pharmaceuticals Corp. (MDGL) | 05-Apr-24 | Option Exercise | 27,613 | $9.45 | $260,943.00 | 3% 841.27K to 868.89K | |
| 05-Apr-24 8:50 PM View: | Friedman Paul A Director | Synta Pharmaceuticals Corp. (MDGL) | 05-Apr-24 | Planned Option Sale | 27,613 | $243.40 | $6,721,080.00 | (3%) 868.89K to 841.27K | |
| 05-Apr-24 8:50 PM View: | Taub Rebecca Pres., R&D, and CMO Director | Synta Pharmaceuticals Corp. (MDGL) | 05-Apr-24 | Option Exercise | 27,506 | $9.45 | $259,932.00 | 2% 1.11M to 1.14M | |
| 05-Apr-24 8:50 PM View: | Taub Rebecca Pres., R&D, and CMO Director | Synta Pharmaceuticals Corp. (MDGL) | 04-Apr-24 | Planned Option Sale | 18,537 | $242.91 | $4,502,820.00 | (2%) 1.13M to 1.11M | |
| 05-Apr-24 8:50 PM View: | Friedman Paul A Director | Synta Pharmaceuticals Corp. (MDGL) | 04-Apr-24 | Option Exercise | 18,710 | $9.45 | $176,810.00 | 2% 841.27K to 859.99K | |
| 05-Apr-24 8:50 PM View: | Friedman Paul A Director | Synta Pharmaceuticals Corp. (MDGL) | 04-Apr-24 | Planned Option Sale | 18,710 | $242.96 | $4,545,720.00 | (2%) 859.99K to 841.27K | |
| 05-Apr-24 8:50 PM View: | Taub Rebecca Pres., R&D, and CMO Director | Synta Pharmaceuticals Corp. (MDGL) | 04-Apr-24 | Option Exercise | 18,537 | $9.45 | $175,175.00 | 2% 1.11M to 1.13M | |
| 05-Apr-24 8:50 PM View: | Friedman Paul A Director | Synta Pharmaceuticals Corp. (MDGL) | 03-Apr-24 | Planned Option Sale | 27,407 | $245.12 | $6,718,000.00 | (3%) 868.68K to 841.27K | |
| 05-Apr-24 8:50 PM View: | Taub Rebecca Pres., R&D, and CMO Director | Synta Pharmaceuticals Corp. (MDGL) | 03-Apr-24 | Option Exercise | 27,845 | $9.45 | $263,135.00 | 2% 1.11M to 1.14M | |
| 05-Apr-24 8:50 PM View: | Taub Rebecca Pres., R&D, and CMO Director | Synta Pharmaceuticals Corp. (MDGL) | 03-Apr-24 | Planned Option Sale | 27,845 | $245.14 | $6,825,980.00 | (2%) 1.14M to 1.11M | |
| 05-Apr-24 8:50 PM View: | Friedman Paul A Director | Synta Pharmaceuticals Corp. (MDGL) | 03-Apr-24 | Option Exercise | 27,407 | $9.45 | $258,996.00 | 3% 841.27K to 868.68K | |
| 03-Apr-24 8:44 PM View: | Bate Kenneth Director | Synta Pharmaceuticals Corp. (MDGL) | 02-Apr-24 | Planned Option Sale | 11,212 | $244.49 | $2,741,220.00 | (90%) 12.41K to 1.2K | |
| 03-Apr-24 8:41 PM View: | Daly James M Director | Synta Pharmaceuticals Corp. (MDGL) | 02-Apr-24 | Planned Option Sale | 10,912 | $244.51 | $2,668,090.00 | (90%) 12.11K to 1.2K | |
| 03-Apr-24 8:44 PM View: | Bate Kenneth Director | Synta Pharmaceuticals Corp. (MDGL) | 02-Apr-24 | Option Exercise | 11,212 | $105.08 | $1,178,160.00 | 936% 1.2K to 12.41K | |
| 03-Apr-24 8:41 PM View: | Daly James M Director | Synta Pharmaceuticals Corp. (MDGL) | 02-Apr-24 | Option Exercise | 10,912 | $105.08 | $1,146,630.00 | 911% 1.2K to 12.11K | |
| 03-Apr-24 8:44 PM View: | Bate Kenneth Director | Synta Pharmaceuticals Corp. (MDGL) | 01-Apr-24 | Planned Option Sale | 21,277 | $257.26 | $5,473,780.00 | (95%) 22.48K to 1.2K | |
| 03-Apr-24 8:41 PM View: | Daly James M Director | Synta Pharmaceuticals Corp. (MDGL) | 01-Apr-24 | Planned Option Sale | 21,577 | $257.24 | $5,550,540.00 | (95%) 22.77K to 1.2K | |
| 03-Apr-24 8:44 PM View: | Bate Kenneth Director | Synta Pharmaceuticals Corp. (MDGL) | 01-Apr-24 | Option Exercise | 21,277 | $57.96 | $1,233,190.00 | 1776% 1.2K to 22.48K | |
| 03-Apr-24 8:47 PM View: | Levy Richard S Director | Synta Pharmaceuticals Corp. (MDGL) | 01-Apr-24 | Option Exercise | 11,000 | $63.92 | $703,160.00 | 107% 10.3K to 21.3K | |
| 03-Apr-24 8:41 PM View: | Daly James M Director | Synta Pharmaceuticals Corp. (MDGL) | 01-Apr-24 | Option Exercise | 21,577 | $100.79 | $2,174,710.00 | 1801% 1.2K to 22.77K | |
| 03-Apr-24 8:47 PM View: | Levy Richard S Director | Synta Pharmaceuticals Corp. (MDGL) | 01-Apr-24 | Planned Option Sale | 11,000 | $257.48 | $2,832,330.00 | (52%) 21.3K to 10.3K | |
| 25-Jan-24 6:04 PM View: | Huntsman Carole Chief Commercial Officer | Synta Pharmaceuticals Corp. (MDGL) | 23-Jan-24 | Grant | 3,639 | -- | -- | 46% 7.83K to 11.47K | |
| 25-Jan-24 3:24 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 23-Jan-24 | Grant | 3,639 | -- | -- | 25% 14.58K to 18.22K | |
| 25-Jan-24 5:54 PM View: | Taub Rebecca Pres., R&D, and CMO Director | Synta Pharmaceuticals Corp. (MDGL) | 23-Jan-24 | Grant | 5,786 | -- | -- | < 1% 1.11M to 1.11M | |
| 25-Jan-24 3:24 PM View: | Sibold William John President and CEO Director | Synta Pharmaceuticals Corp. (MDGL) | 23-Jan-24 | Grant | 12,250 | -- | -- | 25% 50.0K to 62.25K | |
| 25-Jan-24 5:50 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 23-Jan-24 | Grant | 1,419 | -- | -- | 28% 5.12K to 6.54K | |
| 25-Jan-24 3:29 PM View: | Howarth Alex G. Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 23-Jan-24 | Grant | 4,803 | -- | -- | 34% 13.93K to 18.74K | |
| 18-Jan-24 1:45 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 16-Jan-24 | Payment of Exercise | 550 | $243.92 | $134,156.00 | (10%) 5.67K to 5.12K | |
| 18-Jan-24 1:39 PM View: | Howarth Alex G. Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 16-Jan-24 | Payment of Exercise | 1,067 | $243.92 | $260,263.00 | (7%) 15.0K to 13.93K | |
| 18-Jan-24 1:52 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 16-Jan-24 | Payment of Exercise | 949 | $243.92 | $231,480.00 | (6%) 15.53K to 14.58K | |
| 18-Jan-24 1:46 PM View: | Taub Rebecca Pres., R&D, and CMO Director | Synta Pharmaceuticals Corp. (MDGL) | 16-Jan-24 | Payment of Exercise | 1,546 | $243.92 | $377,100.00 | (< 1%) 1.11M to 1.11M | |
| 18-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 15-Dec-23 | Option Exercise | 2,000 | $87.92 | $175,840.00 | 35% 5.67K to 7.67K | |
| 18-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 15-Dec-23 | Option Sale | 2,000 | $238.50 | $477,000.00 | (26%) 7.67K to 5.67K | |
| 18-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 14-Dec-23 | Private Option Sale | 2,000 | $232.50 | $465,000.00 | (26%) 7.67K to 5.67K | |
| 18-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 14-Dec-23 | Option Exercise | 2,000 | $87.92 | $175,840.00 | 35% 5.67K to 7.67K | (7%) |
| 14-Dec-23 6:10 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 14-Dec-23 | Purchase | 20,633 | $228.32 | $4,710,890.00 | < 1% 3.75M to 3.77M | |
| 14-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 13-Dec-23 | Option Exercise | 2,500 | $87.92 | $219,800.00 | 44% 5.67K to 8.17K | |
| 14-Dec-23 6:10 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 13-Dec-23 | Purchase | 81,159 | $219.39 | $17,805,700.00 | 4% 2.06M to 2.14M | |
| 14-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 13-Dec-23 | Option Sale | 2,500 | $225.40 | $563,500.00 | (31%) 8.17K to 5.67K | |
| 14-Dec-23 6:09 PM View: | Baker Bros Advisors LLC Director | Synta Pharmaceuticals Corp. (MDGL) | 12-Dec-23 | Purchase | 34,578 | $218.31 | $7,548,620.00 | 2% 1.84M to 1.88M | |
| 14-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 12-Dec-23 | Private Option Sale | 1,300 | $217.85 | $283,200.00 | (19%) 6.97K to 5.67K | |
| 14-Dec-23 4:30 PM View: | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Synta Pharmaceuticals Corp. (MDGL) | 12-Dec-23 | Option Exercise | 1,300 | $87.92 | $114,296.00 | 23% 5.67K to 6.97K | (7%) |
| 11-Dec-23 7:25 PM View: | Craves Fred B Director | Synta Pharmaceuticals Corp. (MDGL) | 07-Dec-23 | Disposition (other) | 1,556,590 | -- | -- | (76%) 2.05M to 489.69K | |
| 06-Dec-23 4:30 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 05-Dec-23 | Option Sale | 1,000 | $227.33 | $227,330.00 | (6%) 16.53K to 15.53K | |
| 06-Dec-23 4:30 PM View: | Lynch Brian Joseph SVP and General Counsel | Synta Pharmaceuticals Corp. (MDGL) | 05-Dec-23 | Option Exercise | 1,000 | $87.09 | $87,090.00 | 6% 15.53K to 16.53K |
